Company News: Merus reaches pivotal milestone in bispecific antibody collaboration with ONO PHARMACEUTICAL CO., LTD.

– Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies –

Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has reached a preclinical milestone in a bispecific antibody research and license collaboration with ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan, ”ONO”) triggering a payment. The milestone is for achieving preclinical proof-of-mechanism with a lead bispecific antibody directed against a target combination relevant in the treatment of autoimmune disease.